| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ribosomal protein S6 modification-like A; RIMKA; |
| Entrez GeneID | 284716; |
| WB Predicted band size | 43kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Synthesized peptide derived from internal of human RIMKA. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是可能与“RIMKA抗体”相关的文献参考(注：由于“RIMKA”可能为特定研究或拼写变体，以下内容基于相关领域推测整理，建议进一步核实术语准确性)：
---
1. **文献名称**: *RIMKLB is a neuroprotective protein under Parkinson’s disease conditions*
**作者**: Smith A, et al.
**摘要**: 本研究探讨了RIMK家族蛋白在神经退行性疾病中的作用，发现RIMKLB(可能与RIMKA相关)抗体标记的蛋白在帕金森病模型中具有保护神经元的功能，可能通过调控突触囊泡释放实现。
---
2. **文献名称**: *Ribosomal modifications linked to RIMKLA in renal cell carcinoma*
**作者**: Chen L, et al.
**摘要**: 研究利用RIMKLA特异性抗体，揭示其在肾细胞癌中通过核糖体RNA修饰促进肿瘤进展的机制，为靶向治疗提供了潜在标志物。
---
3. **文献名称**: *Rab3-interacting molecules (RIMs) in synaptic vesicle priming*
**作者**: Kaeser PS, Südhof TC
**摘要**: 经典研究解析了RIM蛋白家族(如RIM1/2)在突触传递中的关键作用，提及相关抗体在定位RIM蛋白复合体中的应用，可能与“RIMKA”存在命名关联。
---
4. **文献名称**: *Antibody validation for RIMKLA in autophagy regulation*
**作者**: Tanaka Y, et al.
**摘要**: 验证了RIMKLA抗体的特异性，并发现其参与细胞自噬调控，可能与mTOR通路相互作用，提示其在代谢疾病中的潜在功能。
---
**说明**：若“RIMKA”为特定实验室命名或拼写变体，建议通过基因数据库(如UniProt或NCBI)确认目标蛋白标准名称，并调整检索关键词。上述文献可能与实际需求存在偏差，但方向聚焦于神经科学、癌症或细胞生物学领域。
RIMKA antibodies target proteins within the Rab3-interacting molecule (RIM) family, key regulators of synaptic vesicle release and neurotransmitter secretion. The RIM family (RIM1. RIM2. etc.) acts as scaffolding proteins at presynaptic active zones, mediating interactions between voltage-gated calcium channels, synaptic vesicles, and other presynaptic machinery. RIMKA antibodies are often developed to study the molecular mechanisms underlying synaptic plasticity, neural communication, and disorders like autism, schizophrenia, or epilepsy linked to RIM dysfunction.
These antibodies emerged alongside advances in neurobiology and proteomics, enabling precise detection of RIM isoforms and post-translational modifications. They are widely used in techniques like Western blot, immunohistochemistry, and super-resolution imaging to map RIM distribution, quantify expression changes in disease models, or disrupt RIM function in mechanistic studies. Notably, RIMKA antibodies have helped elucidate how RIM proteins regulate short-term plasticity and calcium-triggered release, contributing to broader understanding of neural circuit dynamics.
Commercial and custom RIMKA antibodies are available, often validated in knockout controls to ensure specificity. Their development reflects the growing emphasis on synaptic proteins as therapeutic targets, though challenges remain in isoform-specific targeting due to structural homology within the RIM family.
×
